胆汁生物标志物及其在胆道肿瘤中的免疫调节作用的研究进展。
Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.
机构信息
Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
出版信息
Front Immunol. 2022 Oct 28;13:1049812. doi: 10.3389/fimmu.2022.1049812. eCollection 2022.
Abstract
Biliary tract cancers (BTCs), including cholangiocarcinoma and gallbladder carcinoma, originate from the biliary epithelium and have a poor prognosis. Surgery is the only choice for cure in the early stage of disease. However, most patients are diagnosed in the advanced stage and lose the chance for surgery. Early diagnosis could significantly improve the prognosis of patients. Bile has complex components and is in direct contact with biliary tract tumors. Bile components are closely related to the occurrence and development of biliary tract tumors and may be applied as biomarkers for BTCs. Meanwhile, arising evidence has confirmed the immunoregulatory role of bile components. In this review, we aim to summarize and discuss the relationship between bile components and biliary tract cancers and their ability as biomarkers for BTCs, highlighting the role of bile components in regulating immune response, and their promising application prospects.
摘要
胆道癌（BTCs）包括胆管癌和胆囊癌，起源于胆道上皮，预后不良。手术是疾病早期治愈的唯一选择。然而，大多数患者在晚期被诊断出来，失去了手术机会。早期诊断可以显著改善患者的预后。胆汁具有复杂的成分，并与胆道肿瘤直接接触。胆汁成分与胆道肿瘤的发生发展密切相关，可能作为 BTCs 的生物标志物应用。同时，越来越多的证据证实了胆汁成分的免疫调节作用。在这篇综述中，我们旨在总结和讨论胆汁成分与胆道癌之间的关系及其作为 BTCs 生物标志物的能力，重点阐述胆汁成分在调节免疫反应中的作用及其有前途的应用前景。
相似文献
1
Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers.胆汁生物标志物及其在胆道肿瘤中的免疫调节作用的研究进展。
Front Immunol. 2022 Oct 28;13:1049812. doi: 10.3389/fimmu.2022.1049812. eCollection 2022.
2
Immunotherapy in Biliary Tract Cancers: Where Are We?胆管癌的免疫治疗：我们在哪里？
Curr Oncol Rep. 2022 Dec;24(12):1821-1828. doi: 10.1007/s11912-022-01328-7. Epub 2022 Oct 4.
3
BRCAness in biliary tract cancer: a new prognostic and predictive biomarker?胆管癌中的“BRCA样”特征：一种新的预后和预测生物标志物？
Biomark Med. 2023 Jan;17(1):51-57. doi: 10.2217/bmm-2022-0664. Epub 2023 Mar 30.
4
Targeted therapies in advanced biliary tract cancers-a narrative review.晚期胆道癌的靶向治疗：叙述性综述。
Chin Clin Oncol. 2023 Apr;12(2):14. doi: 10.21037/cco-22-93. Epub 2023 Mar 13.
5
The epidemiological trends of biliary tract cancers in the United States of America.美国胆道癌的流行病学趋势。
BMC Gastroenterol. 2022 Dec 29;22(1):546. doi: 10.1186/s12876-022-02637-8.
6
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.胆道癌的分子特征可预测化疗和程序性死亡 1/程序性死亡配体 1 阻断反应。
Hepatology. 2021 Oct;74(4):1914-1931. doi: 10.1002/hep.31862. Epub 2021 Jul 29.
7
How I treat biliary tract cancer.我如何治疗胆道癌。
ESMO Open. 2022 Feb;7(1):100378. doi: 10.1016/j.esmoop.2021.100378. Epub 2022 Jan 13.
8
The state of therapy modalities in clinic for biliary tract cancer.胆道癌临床治疗方法的现状。
Front Biosci (Landmark Ed). 2022 Jun 8;27(6):185. doi: 10.31083/j.fbl2706185.
9
Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers.检测活检标本和胆汁中端粒酶逆转录酶mRNA用于诊断胆道癌。
Int J Mol Med. 2001 Mar;7(3):281-7. doi: 10.3892/ijmm.7.3.281.
10
Biliary Tract Cancer: Molecular Biology of Precursor Lesions.胆道肿瘤：癌前病变的分子生物学
Semin Liver Dis. 2023 Nov;43(4):472-484. doi: 10.1055/a-2207-9834. Epub 2023 Nov 9.
引用本文的文献
1
Cholangiocarcinoma: The era of liquid biopsy.胆管癌：液体活检时代。
World J Gastroenterol. 2025 Mar 21;31(11):104170. doi: 10.3748/wjg.v31.i11.104170.
2
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective.胆囊癌的液体活检：当前证据与未来展望。
J Liq Biopsy. 2024 Nov 26;6:100280. doi: 10.1016/j.jlb.2024.100280. eCollection 2024 Dec.
3
Bile-Derived cfDNA of Syncytin-1 and SLC7A11 as a Potential Molecular Marker for Early Diagnosis of Cholangiocarcinoma.作为胆管癌早期诊断潜在分子标志物的源自胆汁的合胞素-1和溶质载体家族7成员11的循环游离DNA
J Gastrointest Cancer. 2025 Jan 28;56(1):55. doi: 10.1007/s12029-025-01180-5.
4
Bile molecular landscape provides pathological insight and classifies signatures predictive of carcinoma of the gall bladder.胆汁分子图谱提供了病理学见解，并对预测胆囊癌的特征进行了分类。
Mol Ther Oncol. 2024 Nov 6;32(4):200904. doi: 10.1016/j.omton.2024.200904. eCollection 2024 Dec 19.
5
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma.REACH-01研究方案：一项关于肝动脉灌注化疗（HAIC）序贯经动脉化疗栓塞（TAE）联合替雷利珠单抗和索凡替尼治疗不可切除肝内胆管癌的单臂、开放标签前瞻性研究。
Front Pharmacol. 2024 Nov 18;15:1435639. doi: 10.3389/fphar.2024.1435639. eCollection 2024.
6
MicroRNAs as Bile-based biomarkers in pancreaticobiliary cancers (MIRABILE): a cohort study.微小RNA作为胰胆管癌基于胆汁的生物标志物（MIRABILE）：一项队列研究。
Int J Surg. 2024 Oct 1;110(10):6518-6527. doi: 10.1097/JS9.0000000000001888.
7
Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma.不同液体活检成分在肝细胞癌中的临床应用
J Pers Med. 2024 Apr 15;14(4):420. doi: 10.3390/jpm14040420.
8
Comparison of clinicopathological characteristics and survival outcomes between gallbladder mucinous adenocarcinoma and gallbladder adenocarcinoma: A propensity score-matched study.胆囊黏液腺癌与胆囊腺癌的临床病理特征及生存结果比较：一项倾向评分匹配研究
World J Gastrointest Oncol. 2023 Aug 15;15(8):1436-1450. doi: 10.4251/wjgo.v15.i8.1436.
9
SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1.SMAD4 通过调节 STING1 的表达来调控胆管癌的进展。
J Cell Mol Med. 2023 Sep;27(17):2547-2561. doi: 10.1111/jcmm.17857. Epub 2023 Jul 24.
10
Development and validation of prognostic nomograms in patients with gallbladder mucinous adenocarcinoma: A population-based study.胆囊黏液腺癌患者预后列线图的开发与验证：一项基于人群的研究。
Front Oncol. 2022 Dec 14;12:1084445. doi: 10.3389/fonc.2022.1084445. eCollection 2022.
本文引用的文献
1
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.Wnt-TCF7-SOX9轴在FGF7-FGFR2自分泌途径中促进胆管癌增殖和培米替尼耐药。
Oncogene. 2022 May;41(20):2885-2896. doi: 10.1038/s41388-022-02313-x. Epub 2022 Apr 15.
2
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.SIRT5 缺失促进胆汁酸诱导的免疫抑制微环境和肝癌发生。
J Hepatol. 2022 Aug;77(2):453-466. doi: 10.1016/j.jhep.2022.02.030. Epub 2022 Mar 12.
3
Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.乙醛脱氢酶 3B2 通过增加整合素β 1 的表达促进胆管癌的增殖和侵袭。
Cell Death Dis. 2021 Dec 14;12(12):1158. doi: 10.1038/s41419-021-04451-8.
4
Importance of Bile Composition for Diagnosis of Biliary Obstructions.胆汁成分对于胆道梗阻诊断的重要性。
Molecules. 2021 Nov 30;26(23):7279. doi: 10.3390/molecules26237279.
5
The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.Smad4-MYO18A-PP1A 复合物通过抑制胆管癌细胞中的 PAK1 来调节 β-连环蛋白磷酸化和培米替尼耐药性。
Cell Death Differ. 2022 Apr;29(4):818-831. doi: 10.1038/s41418-021-00897-7. Epub 2021 Nov 19.
6
Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer.胆管癌抗血管生成机制研究与临床治疗的最新进展
Front Oncol. 2021 Oct 28;11:777617. doi: 10.3389/fonc.2021.777617. eCollection 2021.
7
Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.通过胆汁中的甲基化标记物对原发性硬化性胆管炎患者胆管癌进行早期、准确的检测。
Hepatology. 2022 Jan;75(1):59-73. doi: 10.1002/hep.32125. Epub 2021 Dec 5.
8
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures.胆汁无细胞游离 DNA 的下一代测序用于恶性胆道狭窄患者的早期检测。
Gut. 2022 Jun;71(6):1141-1151. doi: 10.1136/gutjnl-2021-325178. Epub 2021 Jul 20.
9
FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.成纤维细胞生长因子 19 和 FGFR4 通过依赖于 GPBAR1-cAMP-EGR1 轴的自分泌途径促进胆囊癌的进展。
Oncogene. 2021 Jul;40(30):4941-4953. doi: 10.1038/s41388-021-01850-1. Epub 2021 Jun 23.
10
HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.HMGA1-TRIP13 轴通过 c-Myc 依赖性正反馈环促进肝门部胆管癌的干性和上皮间质转化。
J Exp Clin Cancer Res. 2021 Mar 1;40(1):86. doi: 10.1186/s13046-021-01890-1.
Zotero 插件